Marker Therapeutics Past Earnings Performance
Past criteria checks 0/6
Marker Therapeutics has been growing earnings at an average annual rate of 42.4%, while the Biotechs industry saw earnings growing at 17.7% annually. Revenues have been growing at an average rate of 68.6% per year.
Key information
42.4%
Earnings growth rate
68.6%
EPS growth rate
Biotechs Industry Growth | -14.6% |
Revenue growth rate | 68.6% |
Return on equity | -100.0% |
Net Margin | -424.2% |
Last Earnings Update | 31 Dec 2023 |
Recent past performance updates
No updates
Recent updates
Revenue & Expenses BreakdownBeta
How Marker Therapeutics makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
---|---|---|---|---|
31 Dec 23 | 3 | -14 | 7 | 0 |
30 Sep 23 | 9 | -25 | 9 | 0 |
30 Jun 23 | 9 | -27 | 11 | 0 |
31 Mar 23 | 9 | -24 | 11 | 0 |
31 Dec 22 | 4 | -20 | 11 | 0 |
30 Sep 22 | 4 | -26 | 13 | 0 |
30 Jun 22 | 3 | -33 | 13 | 0 |
31 Mar 22 | 2 | -43 | 14 | 0 |
31 Dec 21 | 1 | -42 | 13 | 0 |
30 Sep 21 | 0 | -41 | 12 | 0 |
30 Jun 21 | 0 | -36 | 12 | 0 |
31 Mar 21 | 0 | -31 | 11 | 0 |
31 Dec 20 | 0 | -29 | 10 | 0 |
30 Sep 20 | 1 | -25 | 10 | 0 |
30 Jun 20 | 1 | -23 | 10 | 0 |
31 Mar 20 | 0 | -23 | 10 | 0 |
31 Dec 19 | 0 | -21 | 10 | 0 |
30 Sep 19 | 0 | -152 | 25 | 0 |
30 Jun 19 | 0 | -151 | 27 | 0 |
31 Mar 19 | 0 | -150 | 26 | -2 |
31 Dec 18 | 0 | -148 | 24 | 0 |
30 Sep 18 | 0 | -15 | 8 | -4 |
30 Jun 18 | 0 | -15 | 7 | -2 |
31 Mar 18 | 0 | -12 | 7 | 1 |
31 Dec 17 | 0 | -11 | 6 | 0 |
30 Sep 17 | 0 | -10 | 6 | 4 |
30 Jun 17 | 0 | -8 | 5 | 4 |
31 Mar 17 | 0 | 0 | 5 | 4 |
31 Dec 16 | 0 | -2 | 5 | 4 |
30 Sep 16 | 0 | -3 | 6 | 3 |
30 Jun 16 | 0 | 28 | 5 | 3 |
31 Mar 16 | 0 | -38 | 5 | 2 |
31 Dec 15 | 0 | -34 | 4 | 2 |
30 Sep 15 | 0 | -33 | 2 | 2 |
30 Jun 15 | 0 | -63 | 3 | 1 |
31 Mar 15 | 0 | -2 | 2 | 1 |
31 Dec 14 | 0 | -31 | 3 | 0 |
30 Sep 14 | 0 | -34 | 4 | 1 |
30 Jun 14 | 0 | -33 | 3 | 1 |
31 Mar 14 | 0 | -35 | 2 | 1 |
31 Dec 13 | 0 | -6 | 2 | 1 |
30 Sep 13 | 0 | -4 | 2 | 1 |
Quality Earnings: GX1 is currently unprofitable.
Growing Profit Margin: GX1 is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: GX1 is unprofitable, but has reduced losses over the past 5 years at a rate of 42.4% per year.
Accelerating Growth: Unable to compare GX1's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: GX1 is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-14.4%).
Return on Equity
High ROE: GX1 has a negative Return on Equity (-99.95%), as it is currently unprofitable.